JAK Janus Kinase

Cat.No.	Name	Information
M3030	S-Ruxolitinib	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820	Tofacitinib	Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660	AZ 960	AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646	AG490	AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733	TG101348	TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787	INCB18424	Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo.
M5944	Ruxolitinib phosphate	Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616	Tofacitinib citrate	Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346	Filgotinib	Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044	AZD1480	AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M49612	MMT3-72-M2	MMT3-72-M2 is an MMT3-72 metabolite.
M49611	MMT3-72	MMT3-72 is a weak inhibitor of JAK1.
M49610	JAK-IN-5	JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
M49609	JAK-IN-4	JAK-IN-4 is a proagent of a JAK inhibitor, effective in murine collagen induced arthritis model.
M49608	JAK-IN-35	JAK-IN-35 is a JAK2 inhibitor that canb be used in cancer research.
M49607	JAK-IN-34	JAK-IN-34 is a potent against of JAKs with IC50 values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively.
M49606	JAK-IN-33	JAK-IN-33 is a JAK inhibitor.
M49604	JAK-IN-24	JAK-IN-24 is a JAK inhibitor, with IC50s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively.
M49603	JAK-IN-21	JAK-IN-21 is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively.
M49602	JAK-IN-20	JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively.
M49601	JAK-IN-19	JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7).
M49600	JAK-IN-18	JAK-IN-18 is a potent inhibitor of JAK.
M49599	JAK-IN-17	JAK-IN-17 is a potent inhibitor of JAK.
M49598	JAK-IN-15	JAK-IN-15 is a JAK inhibitor.
M49597	JAK-IN-14	JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM.
M49596	JAK-IN-10	JAK-IN-10 is a JAK inhibitor.
M49595	JAK3-IN-9	JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM.
M49594	JAK3-IN-7	JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM.
M49593	JAK3-IN-12	JAK3-IN-12 is a highly potent JAK3 inhibitor with IC50 values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively.
M49592	JAK3-IN-11	JAK3-IN-11 , a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3.

By Signaling Pathways

By Product Type

Signaling Pathways

JAK Janus Kinase

Get to Know Us

Customer Support

Resources

Contact Us